Lumen Biosciences
Facts
- HQ
- Seattle
- Sectors
- Biotechnology, Biopharmaceuticals, Synthetic biology
- Founded
- 2017 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Lumen Bioscience Inc Seattle business license
- Stage
- Startup
- Founders
- Brian Finrow, Jim Roberts
Seattle Biotech Lumen Bioscience Raises $30M Series C Extension, Adds Microsoft Vet Jeff Raikes to Board
Seattle biotech startup Lumen Bioscience raised a $30 million Series C extension led by WestRiver Group, bringing total funding to $186.8 million to advance its oral biologic drugs. The company also added Microsoft veteran Jeff Raikes to its board and announced several leadership updates.
Lumen Bioscience adds Jeff Raikes to board, promotes executives and secures $30M Series C extension led by WestRiver Group
Lumen Bioscience announced board and leadership changes—including Jeff Raikes joining as an independent director, promotions of Nhi Khuong and Kole Krieger, and appointment of David Saunders—and elected Erik Anderson as Vice Chairman. The company also closed an oversubscribed $30 million Series C extension led by WestRiver Group with participation from the Gates Foundation and several new investors to support its orally delivered biologics clinical pipeline.
A-Alpha Bio raises $20M Series A led by Madrona to expand Seattle lab and scale protein-discovery platform
University of Washington spinout A-Alpha Bio raised $20 million in Series A funding led by Madrona Venture Group to expand downtown Seattle lab space and grow its machine-learning team for its protein-discovery platform. The company combines computational tools and yeast-based experiments to generate large protein-interaction datasets used to predict therapeutic protein candidates for diseases including COVID-19.
People
-
Jeff Raikes Board Member
